Nuclear Medicine and Molecular Imaging

, Volume 48, Issue 2, pp 163–165 | Cite as

Splenosis Mimicking Relapse of a Neuroendocrine Tumor at Gallium-68-DOTATOC PET/CT

  • Giorgio Treglia
  • Luca Giovanella
  • Barbara Muoio
  • Carmelo Caldarella
Interesting Image
First Online:
Received:
Revised:
Accepted:

Keywords

Imaging Method Neuroendocrine Tumor Core Biopsy Inflammatory Lesion Increase Serum Level 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Notes

Conflict of Interest

Giorgio Treglia, Luca Giovanella, Barbara Muoio and Carmelo Caldarella declare that they have no conflicts of interest.

Funding

None.

References

  1. 1.
    Treglia G, Castaldi P, Rindi G, et al. Diagnostic performance of gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis. Endocrine. 2012;42:80–7.PubMedCrossRefGoogle Scholar
  2. 2.
    Treglia G, Cason E, Fagioli G. Recent applications of nuclear medicine in diagnostics (first part). Ital J Med. 2010;4:84–91.CrossRefGoogle Scholar
  3. 3.
    Rufini V, Baum RP, Castaldi P, et al. Role of PET/CT in the functional imaging of endocrine pancreatic tumors. Abdom Imaging. 2012;37:1004–20.PubMedCrossRefGoogle Scholar
  4. 4.
    Oh J-R, Kulkarni H, Carreras C, et al. Ga-68 Somatostatin receptor PET/CT in von Hippel-Lindau disease. Nucl Med Mol Imaging. 2012;46:129–33.CrossRefGoogle Scholar
  5. 5.
    Treglia G, Salomone E, Petrone G, et al. A rare case of ectopic adrenocorticotropic hormone syndrome caused by a metastatic neuroendocrine tumor of the pancreas detected by 68Ga-DOTANOC and 18F-FDG PET/CT. Clin Nucl Med. 2013;38:e306–8.PubMedCrossRefGoogle Scholar
  6. 6.
    Treglia G, Inzani F, Campanini N, et al. A case of insulinoma detected by 68Ga-DOTANOC PET/CT and missed by 18F-dihydroxyphenylalanine PET/CT. Clin Nucl Med. 2013;38:e267–70.PubMedCrossRefGoogle Scholar
  7. 7.
    Treglia G, Plastino F, Campitiello M. Staging and treatment response evaluation in a metastatic neuroendocrine tumor of the pancreas with G2 grading: insights from multimodality diagnostic approach by F-18-FDG and Ga-68-DOTANOC PET/CT. Endocrine. 2013;43:729–31.PubMedCrossRefGoogle Scholar
  8. 8.
    Castaldi P, Rufini V, Treglia G, et al. Impact of 111In-DTPA-octreotide SPECT/CT fusion images in the management of neuroendocrine tumours. Radiol Med. 2008;113:1056–67.PubMedCrossRefGoogle Scholar
  9. 9.
    Treglia G, Farchione A, Stefanelli A, et al. Masking effect of chronic pancreatitis in the interpretation of somatostatin receptor positron emission tomography in pancreatic neuroendocrine tumors. Pancreas. 2013;42:726–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Shetty D, Lee Y-S, Jeong JM. 68Ga-labeled radiopharmaceuticals for positron emission tomography. Nucl Med Mol Imaging. 2010;44:233–40.CrossRefGoogle Scholar
  11. 11.
    Kulkarni HR, Prasad V, Kaemmerer D, et al. High uptake of (68)Ga-DOTATOC in spleen as compared to splenosis: measurement by PET/CT. Recent Results Cancer Res. 2013;194:373–8.PubMedCrossRefGoogle Scholar

Copyright information

© Korean Society of Nuclear Medicine 2013

Authors and Affiliations

  • Giorgio Treglia
    • 1
  • Luca Giovanella
    • 1
  • Barbara Muoio
    • 2
  • Carmelo Caldarella
    • 3
  1. 1.Nuclear Medicine and PET/CT CenterOncology Institute of Southern SwitzerlandBellinzonaSwitzerland
  2. 2.School of MedicineCatholic UniversityRomeItaly
  3. 3.Nuclear MedicineCatholic UniversityRomeItaly

Personalised recommendations